142 related articles for article (PubMed ID: 36087876)
21. Iris melanoma: risk factors for metastasis in 169 consecutive patients.
Shields CL; Shields JA; Materin M; Gershenbaum E; Singh AD; Smith A
Ophthalmology; 2001 Jan; 108(1):172-8. PubMed ID: 11150284
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with elevated intraocular pressure in eyes with iris melanoma.
Shields CL; Materin MA; Shields JA; Gershenbaum E; Singh AD; Smith A
Br J Ophthalmol; 2001 Jun; 85(6):666-9. PubMed ID: 11371484
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.
Mahdjoubi A; Najean M; Lemaitre S; Dureau S; Dendale R; Levy C; Rouic LL; Desjardins L; Cassoux N
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):411-420. PubMed ID: 29116399
[TBL] [Abstract][Full Text] [Related]
24. No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.
Sabazade S; Herrspiegel C; Gill V; Stålhammar G
BMC Cancer; 2021 Nov; 21(1):1270. PubMed ID: 34819035
[TBL] [Abstract][Full Text] [Related]
25. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy.
Conway RM; Poothullil AM; Daftari IK; Weinberg V; Chung JE; O'Brien JM
Arch Ophthalmol; 2006 Jun; 124(6):838-43. PubMed ID: 16769837
[TBL] [Abstract][Full Text] [Related]
26. Ciliary body melanoma with limited nodular extrascleral extension and diffuse iris-angle infiltration treated by whole anterior segment plaque radiotherapy.
Gray ME; Corrêa ZM; Augsburger JJ; Barrett W
Int Ophthalmol; 2007 Aug; 27(4):273-6. PubMed ID: 17468833
[TBL] [Abstract][Full Text] [Related]
27. Proton beam therapy for iris melanoma: a review of 15 cases.
Rundle P; Singh AD; Rennie I
Eye (Lond); 2007 Jan; 21(1):79-82. PubMed ID: 16410818
[TBL] [Abstract][Full Text] [Related]
28. Proton therapy for uveal melanoma in 43 juvenile patients: long-term results.
Petrovic A; Bergin C; Schalenbourg A; Goitein G; Zografos L
Ophthalmology; 2014 Apr; 121(4):898-904. PubMed ID: 24405742
[TBL] [Abstract][Full Text] [Related]
29. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
[TBL] [Abstract][Full Text] [Related]
30. Diffuse Iris Melanoma: Conservative Treatment with Proton Beam Therapy after Limbal Stem Cell Preservation or Enucleation?
Leblanc A; Lumbroso-Le Rouic L; Desjardins L; Dendale R; Cassoux N
Ocul Oncol Pathol; 2019 Oct; 5(6):396-401. PubMed ID: 31768362
[TBL] [Abstract][Full Text] [Related]
31. Trabeculectomy in patients with uveal melanoma after proton beam therapy.
Riechardt AI; Cordini D; Rehak M; Hager A; Seibel I; Böker A; Gundlach E; Heufelder J; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1379-85. PubMed ID: 26960442
[TBL] [Abstract][Full Text] [Related]
32. Proton beam therapy for iris melanomas.
Lumbroso-Le Rouic L; Delacroix S; Dendale R; Levy-Gabriel C; Feuvret L; Noel G; Plancher C; Nauraye C; Garcia P; Calugaru V; Asselain B; Desjardins L
Eye (Lond); 2006 Nov; 20(11):1300-5. PubMed ID: 16294207
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
Böker A; Pilger D; Cordini D; Seibel I; Riechardt AI; Joussen AM; Bechrakis NE
Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of Modified Collaborative Ocular Melanoma Study IRIS plaques for treatment of iris, iridociliary, and ciliary body melanoma.
Xu TT; Pulido JS; Deufel CL; Corbin KS; Petersen IA; Dalvin LA
Eye (Lond); 2021 Oct; 35(10):2754-2762. PubMed ID: 33235338
[TBL] [Abstract][Full Text] [Related]
35. Iris melanoma outcomes based on the Cancer Genome Atlas (TCGA) classification in 78 consecutive patients.
Cherkas E; Negretti GS; Zeiger JS; Shields CL
Ophthalmic Genet; 2022 Dec; 43(6):736-741. PubMed ID: 36326016
[TBL] [Abstract][Full Text] [Related]
36. Plaque radiotherapy for residual or recurrent iris melanoma after surgical resection in 32 cases.
Shah SU; Shields CL; Bianciotto C; Emrich J; Komarnicky L; Shields JA
Ophthalmology; 2012 Apr; 119(4):838-842.e2. PubMed ID: 22133794
[TBL] [Abstract][Full Text] [Related]
37. Salvage proton beam therapy in local recurrent uveal melanoma.
Riechardt AI; Cordini D; Dobner B; Seibel I; Gundlach E; Rehak M; Hager A; Stark R; Moser L; Joussen AM
Am J Ophthalmol; 2014 Nov; 158(5):948-56. PubMed ID: 25038327
[TBL] [Abstract][Full Text] [Related]
38. Baerveldt shunts in the treatment of glaucoma secondary to anterior uveal melanoma and proton beam radiotherapy.
Sharkawi E; Oleszczuk JD; Bergin C; Zografos L
Br J Ophthalmol; 2012 Aug; 96(8):1104-7. PubMed ID: 22628537
[TBL] [Abstract][Full Text] [Related]
39. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients.
Shields CL; Naseripour M; Cater J; Shields JA; Demirci H; Youseff A; Freire J
Ophthalmology; 2002 Oct; 109(10):1838-49. PubMed ID: 12359604
[TBL] [Abstract][Full Text] [Related]
40. Incidence and Risk Factors for Secondary Glaucoma in Eyes with Uveal Melanoma.
Stadigh AE; Puska PM; Kivelä TT
Ophthalmol Glaucoma; 2023; 6(1):29-41. PubMed ID: 35964940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
